Printer Friendly

Induced Pluripotent Stem Cell (iPSC) Industry Complete Report 2015 - 2016.

DALLAS, April 2, 2015 /PRNewswire/ --

Lifescienceindustryresearch.com adds "Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report" in its store. Recent months have seen the first iPSC clinical trial in humans, creation of the world's largest iPSC Biobank, major funding awards, a historic challenge to the "Yamanaka Patent", a Supreme Court ruling affecting industry patent rights, the announcement of an iPSC cellular therapy clinic scheduled to open in 2019, and much more. Furthermore, iPSC patent dominance continues to cluster in specific geographic regions, while clinical trial and scientific publication trends give clear indicators of what may happen in the industry in 2015 and beyond.

Is it worth it to get informed about rapidly-evolving market conditions and identify key industry trends that will give an advantage over the competition?

Browse the Report Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report at http://www.lifescienceindustryresearch.com/complete-2013-14-induced-pluripotent-stem-cell-ipsc-industry-report.html .

Induced pluripotent stem cells represent a promising tool for use in the reversal and repair of many previously incurable diseases. The cell type represents one of the most promising advances discovered within the field of stem cell research during the past decade, making this a valuable industry report for both companies and investors to claim in order to optimally position themselves to sell iPSC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial iPSC trends.

Report Applications

This global strategic report is produced for: Management of Stem Cell Product Companies, Management of Stem Cell Therapy Companies, Stem Cell Industry Investors

It is designed to increase your efficiency and effectiveness in:

* Commercializing iPSC products, technologies, and therapies

* Making intelligent investment decisions

* Launching high-demand products

* Selling effectively to your client base

* Increasing revenue

* Taking market share from your competition

Four Primary Areas of Commercialization

There are currently four major areas of commercialization for induced pluripotent stem cells, as described below:

* Drug Development & Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.

* Cellular Therapy: iPSCs can be used for cellular therapy applications, including autologous transplantation and potentially gene therapy. The purpose of cellular therapy is to reverse injury or disease.

* Toxicology Screening: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.

* Stem Cell Biobanking: The goal of stem cell biobanking is to create a repository of stem cell specimens, including source tissue from which iPSCs can be derived, differentiated cell types produced from iPSCs, and disease tissues produced from iPSCs. Large-scale stem cell repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC derived cells produced from both healthy and diseased donors. Importantly, these repositories can also greatly expand the capacity for global research and collaboration.

Order a Copy of Report at http://www.lifescienceindustryresearch.com/purchase?rname=307.

Rapidly-Evolving Market Opportunities for iPSCs

Since the discovery of iPSCs a large and thriving research product market has grown into existence, largely because the cells are completely non-controversial and can be generated directly from adult cells. Today, the number of iPSC products sold worldwide is increasing with double-digit growth. In addition, 22% of all stem cell researchers now self-report having used iPSCs within a research project. It is clear that iPSCs represent a lucrative product market, but methods for commercializing this cell type are still being explored, as clinical studies investigating iPSCs continue to increase in number.

Currently, nearly all clinical studies involving iPSCs are for the creation and evaluation of iPSC lines from specific patient populations in order to determine if these cell lines could be a good model for a disease of interest in that patient population. (See ClinicalTrials.gov for a current list of these trials or view the "Clinical Trial Trend Analysis" section of this report for a full discussion of findings.) However, the first clinical study involving transplant of iPSCs into humans was initiated in August 2013.

Market Leaders Have Begun to Emerge in All Areas of iPSC Development

Finally, market leaders have begun to emerge in all areas of iPSC development, including:

* Drug Development and Discovery: Cellular Dynamics International (CDI) in Madison, Wisconsin

* Cellular Therapy (Therapeutic Applications of iPSCs): RIKEN Center, in Kobe, Japan, and Kyoto University in Kyoto, Japan

* Stem Cell Biobanking: Cellular Dynamics International (CDI) in Madison, Wisconsin

* iPSC Research Products: ReproCELL in Kanagawa, Japan; Thermo Fisher Scientific in Rockville, MD; STEMCELL Technologies in Vancouver, Canada; and BD Biosciences in San Jose, California

End-User Survey of iPSC Scientists

A distinctive feature of this report is an end-user survey of 273 researchers (131 U.S. / 143 International) that identify as having induced pluripotent stem cells as a research focus. These survey findings reveal iPSC researcher needs, technical preferences, key factors influencing buying decisions, and more. The findings can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.

Key Report Findings Include:

* Metrics, Timelines, Tables, and Graphs for the iPSC Industry

* Trend Rate Data for iPSC Grants, Clinical Trials, and Scientific Publications

* Analysis of iPSC Patent Environment, including Key Patents and Patent Trends

* Market Segmentation

* 5-Year Market Size Projections (2015-2019)

* Market Size Estimations, by Market Segment

* Updates on Crucial iPSC Industry and Technology Trends

* Analysis of iPSC Market Leaders, by Market Segment

* Geographical Assessment of iPSC Innovation

* SWOT Analysis for the iPSC Sector (Strengths, Weaknesses, Opportunities, Threats)

* Preferred Species for iPSC Research

* Influential Language for Selling to iPSC Scientists

* Breakdown of the Marketing Methods, including Exposure and Response Rates

* And Much More

Input Sources

The content and statistics contained in this report were compiled using a broad range of sources. These sources include: Stem Cell Grant Funding Database (NIH database), Stem Cell Patent Database (USPTO), Stem Cell Clinical Trial Database (ClinicalTrials.gov), Stem Cell Scientific Publication Database (PubMed), Stem Cell Product Launch Announcements (Trade Journals, Google News), Stem Cell Industry Events (Google News, Google Alerts), Stem Cell Company News (SEC Filings, Investor Publications), International Surveys (Electronically Distributed End-User Surveys) And More.

Connect with Us:

G+ / Google Plus: https://plus.google.com/112612135957880308475/

Twitter: https://twitter.com/LifeSciReports

Facebook: https://www.facebook.com/lifescienceindustryresearch

Feed: http://www.lifescienceindustryresearch.com/feed

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza, 17304, Preston Road, Suite 800, Dallas 75252

Tel: +1-888-391-5441

sales@lifescienceindustryresearch.com
COPYRIGHT 2015 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire Europe
Article Type:Report
Date:Apr 2, 2015
Words:1355
Previous Article:IXcellerate and Ernst&Young Prepare 5 Steps to Comply with Russian Information Law.
Next Article:Roland Jonkhoff Appointed Managing Director of Desso.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters